Rubicon’s mission is to develop novel, practical targeted therapies that will greatly benefit the patient. Rubicon is developing two platform technologies: Fv-Hsp72 for acute indications and Modified Annexin for cancer.

Fv-Hsp72 is a powerful targeted cytoprotectant which can directly deliver Hsp72 into stressed and dying cells in order to salvage them from death. Our primary indication is myocardial infarction and we believe Fv-Hsp72 will help reduce cellular damage to the heart, thereby improving heart function and reducing morbidity. Other indications include acute lung injury and stroke.

Our Modified Annexin program uses Annexin A5, a natural high-affinity phosphatidylserine (PS)-binding protein discovered by Dr. Chris Reutelingsperger at Maastricht University. Dr. Reutelingsperger modified the annexin so that it will not internalize into the cell, which is the normal physiological response for annexin binding to PS. Phosphatidylserine is exposed on the surface of solid tumors and their blood vessels within the tumor microenvironment, but not on healthy cells. Rubicon’s Modified Annexin is able to deliver powerful anti-cancer compounds to a common target found on the surface of tumors and the tumor vasculature.

With a strong, experienced core team and world class collaborators, Rubicon is well positioned to develop our two leading-edge platform technologies.

Rubicon Biotechnology

15375 Barranca Parkway, Suite B-104 Irvine CA 92618